The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers

被引:135
作者
Stange, J
Hassanein, TI
Mehta, R
Mitzner, SR
Bartlett, RH
机构
[1] Univ Calif San Diego, Med Ctr, Ctr Liver, Div Gastroenterol Hepatol, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Med Ctr, Div Nephrol, San Diego, CA 92103 USA
[3] Univ Rostock, Dept Internal Med, Div Nephrol, D-2500 Rostock, Germany
[4] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA
关键词
albumin dialysis; clinical trials; liver failure; liver support; molecular adsorbents recycling system; multicenter trials;
D O I
10.1046/j.1525-1594.2002.06822.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Artificial liver support aims to prolong survival time of patients with liver failure by detoxification. Albumin as a molecular adsorbent in dialysis solution is capable of attracting even tightly albumin-bound toxins from blood into the dialysate if a specific dialysis membrane is used and if the albumin's binding sites are on-line-purified by a sorbent/dialysis-based recycling system (i.e., molecular adsorbents recycling system, or MARS). The MARS technology has been shown to remove water-soluble and albumin-bound toxins and to provide renal support in case of renal failure. Fourteen centers have reported that MARS treatment improved mental status of patients with liver failure and hepatic encephalopathy. In treating liver failure and cholestasis, MARS was associated with hemodynamic stabilization, improvement of hepatic and kidney function, and disappearance of pruritus. In hepatic failure and hepatorenal syndrome, a prospective, randomized, controlled trial of MARS treatment was able to prolong survival time significantly. MARS has been used in 26 patients with acute liver failure or primary graft dysfunction. Nineteen centers reporting on 103 patients have shown that MARS treatment is safe, easy to handle, feasible, and effective.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 56 条
[41]  
SIEWERTDELLE A, 2001, Z GASTROENTEROL S, V39, P48
[42]  
SORKINE P, 2001, Z GASTROENTEROL SS2, V39, P40
[43]   NITRIC-OXIDE CIRCULATES IN MAMMALIAN PLASMA PRIMARILY AS AN S-NITROSO ADDUCT OF SERUM-ALBUMIN [J].
STAMLER, JS ;
JARAKI, O ;
OSBORNE, J ;
SIMON, DI ;
KEANEY, J ;
VITA, J ;
SINGEL, D ;
VALERI, CR ;
LOSCALZO, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7674-7677
[44]   Liver support by extracorporeal blood purification:: A clinical observation [J].
Stange, J ;
Mitzner, SR ;
Klammt, S ;
Freytag, J ;
Peszynski, P ;
Loock, J ;
Hickstein, H ;
Korten, G ;
Schmidt, R ;
Hentschel, J ;
Schulz, M ;
Löhr, M ;
Liebe, S ;
Schareck, W ;
Hopt, UT .
LIVER TRANSPLANTATION, 2000, 6 (05) :603-613
[45]   A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver [J].
Stange, J ;
Mitzner, S .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1996, 19 (11) :677-691
[46]  
Stange J, 1999, ARTIF ORGANS, V23, P319
[47]  
Stange J, 2000, HEPATOLOGY, V32, p612A
[48]  
STANGE J, 1993, ARTIF ORGANS, V17, P809
[49]  
STANTON SA, 1995, DATAMATION, V41, P11
[50]  
STEINER C, 2001, Z GASTROENTEROL S, V39, P52